News NeuroPace, Inc.

Equities

NPCE

US6412881053

Real-time Estimate Cboe BZX Other stock markets 14:30:12 2024-05-02 EDT			5-day change	1st Jan Change
13.98 ^USD	+0.11%		+7.62%	+35.60%

03-15	North American Morning Briefing : Inflation -2-	DJ
03-14	Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024	04-17	GL
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference	03-27	AQ
North American Morning Briefing : Inflation -2-	03-15	DJ
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	03-14	MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating	03-12	MT
NeuroPace Shares Decline Following Q4 Financial Results	03-06	MT
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Transcript : NeuroPace, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M	03-05	MT
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million	03-05	GL
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024	03-05	CI
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating	02-22	MT
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	02-15	AQ
NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary	02-07	CI
Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target	01-30	MT
Transcript : NeuroPace, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	01-11
NeuroPace Preliminary Q4 Revenue Beats Street View; Shares Rise	01-08	MT
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates	01-08	AQ
NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023	01-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NeuroPace, Inc.

Equities

NPCE

US6412881053

Summary

Filters